Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia

NCT03705507 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT03705507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03705507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Lead sponsor
University of Birmingham
Phase
Phase 1/2
Overall status
Terminated
Start date
May 18, 2018
Completion date
May 3, 2023
Enrollment
12 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute lymphoblastic leukemia recurrent, acute lymphoblastic leukemia, adult, acute lymphoblastic leukemia, in relapse, acute lymphoblastic leukemia, pediatric